Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | MYC | P01106 | 2/20 | 0.41 |
| ▸ | MAX | P61244 | 2/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | GART | P22102 | 1/20 | 0.38 |
| ▸ | ATIC | P31939 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005187 | 1.00 | FPR2 (0.54) | FPR2FOLH1MYCMAXP2RY12 | |
| SCHEMBL23005210 | 0.85 | FPR2 (0.51) | FPR2FOLH1MYCMAXP2RY12 | |
| SCHEMBL23005209 | 0.85 | FPR2 (0.51) | FPR2FOLH1MYCMAXP2RY12 | |
| SCHEMBL23005132 | 0.83 | FPR2 (0.62) | FPR2P2RY12CA2CA1 | |
| SCHEMBL23005131 | 0.83 | FPR2 (0.62) | FPR2P2RY12CA2CA1 | |
| SCHEMBL23005125 | 0.83 | FPR2 (0.53) | FPR2FOLH1MYCMAXP2RY12 | |
| SCHEMBL23005126 | 0.83 | FPR2 (0.53) | FPR2FOLH1MYCMAXP2RY12 | |
| SCHEMBL21494638 | 0.77 | MYC (0.46) | MYCMAX | |
| SCHEMBL23005185 | 0.73 | FOLH1 (0.32) | FPR2FOLH1 | |
| SCHEMBL21494596 | 0.71 | FPR2 (1.00) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2023-04-13 | — | — | US | disclosed |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | MEDICINSK FORSKNING (SE) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | FPR2 406/4885FOLH1 282/4885MYC 2305/4885 |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | FPR2 435/4885FOLH1 315/4885MYC 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.